Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference By: Enanta Pharmaceuticals, Inc. via Business Wire September 17, 2023 at 12:00 PM EDT Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain. Date/Time: Sunday, September 17, 2023, from 20:00 – 21:00 CEST / 2:00 – 3:00 PM EDT (Sneak Peak) Date/Time: Monday, September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT Abstract Number: 663 Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity” Location: Poster Hall Exhibit Presenter: Kimberly Mills, PharmD Further information about the ESWI Influenza Conference can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®. View source version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/Contacts Media and Investors Jennifer Viera 617-744-3848 jviera@enanta.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference By: Enanta Pharmaceuticals, Inc. via Business Wire September 17, 2023 at 12:00 PM EDT Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain. Date/Time: Sunday, September 17, 2023, from 20:00 – 21:00 CEST / 2:00 – 3:00 PM EDT (Sneak Peak) Date/Time: Monday, September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT Abstract Number: 663 Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity” Location: Poster Hall Exhibit Presenter: Kimberly Mills, PharmD Further information about the ESWI Influenza Conference can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®. View source version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/Contacts Media and Investors Jennifer Viera 617-744-3848 jviera@enanta.com
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-323, its oral, once-daily, L-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at the 9th European Scientific Working Group on Influenza (ESWI) Influenza Conference on September 17-20, 2023 at the Palacio de Congresos de Valencia in Valencia, Spain. Date/Time: Sunday, September 17, 2023, from 20:00 – 21:00 CEST / 2:00 – 3:00 PM EDT (Sneak Peak) Date/Time: Monday, September 18, 2023, from 19:30 – 21:00 CEST / 1:30 – 3:00 PM EDT Abstract Number: 663 Poster Title: “EDP-323, a First-in-Class, Once-Daily, Oral L-Protein Inhibitor for the Treatment of RSV: Results from a Phase 1 Study in Healthy Subjects and Correlation with In Vitro Antiviral Activity” Location: Poster Hall Exhibit Presenter: Kimberly Mills, PharmD Further information about the ESWI Influenza Conference can be found here. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV). Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®. View source version on businesswire.com: https://www.businesswire.com/news/home/20230917800366/en/